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Abstract
Background: Chondral damage is one of the major sequelae of septic arthritis; occurring even after prompt treatment of
a septic joint. Subsequent loss of joint function can have a significant impact on a patient’s quality of life. Corticosteroids
are known to have beneficial effects on the rate and extent cartilage destruction in arthritis through a variety of mediators
such as synovial RANKL expression, mast cells and pro-inflammatory cytokines. Investigation into sepsis at other sites has
suggested improved outcomes with corticosteroid use despite the theoretical risks. This study therefore set out to review
current literature with regards to a possible beneficial effect for corticosteroids in Septic Arthritis.
Methods: A computerised search of the databases MEDLINE and CINAHL was conducted during November 2014 using
the EBSCOhost web search engine in order to identify research articles relating to the use of corticosteroids in the
treatment of septic arthritis. The search strategy revealed 223 unique articles which were subjected to inclusion/exclusion
criteria assessment. 6 articles were selected for study inclusion. These consisted of 3 human studies (2 double-blind
randomised controlled trials & 1 double-blind non-randomised controlled trial), and 3 animal studies (3 non-blinded
non-randomised controlled trials). Quantitative synthesis (meta-analysis) was only possible regarding two primary
outcomes for two of the included studies – time to normalisation of CRP and duration of IV antibiotic therapy.
Results: All current published evidence in humans is focused upon children. Overall results did however reveal a
consensus between these studies for a reduced duration of symptoms and a reduction in inflammatory markers.
Animal data suggested a protective effect on the articular cartilage with the addition of corticosteroids to
antibiotic therapy. No article noted an adverse effect associated with steroid use. Findings were consistent with
systematic reviews of corticosteroid use in other bacterial infections.
Conclusions: Despite the promising outlook, issues’ regarding generalisability of results and a lack of large
randomised controlled trial data necessitates further assessment of the safety and efficacy of steroid use in adults
before treatment recommendations can be made. Long term safety data and the determinations of the optimum
route, dose and timing of corticosteroids are also required.
Background
Despite modern antibiotic therapy Septic Arthritis still
carries a significant associated morbidity (31.6 %) and
mortality (11.5 %) [1]. The higher incidence of infection
in those of a younger age enhances the magnitude of this
issue. Joint contamination typically occurs through
haematogenous spread but direct inoculation can occur
with intra-articular procedures. Clinical presentation is
usually of a monoarthritis with systemic sepsis. The knee
is most commonly affected, accounting for approximately
50 % of cases [2].
A vast array of pathogenic organisms have been identi-
fied; with gram positive cocci such as Staphylococcus
and Streptococcus are the most commonly seen [3].
Once colonisation has occurred rapid proliferation of
bacteria ensues initiating an acute inflammatory re-
sponse. There is activation of Toll-like receptors with
substantial release of pro-inflammatory cytokines such
as Interleukin (IL)-1 beta, Tumour Necrosis Factor
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(TNF)-alpha, IL-17 and IL-6 [3]. These molecules stimu-
late osteoclast differentiation and bone reabsorption as
well as matrix metalloproteinase (MMP) release leading
to subsequent bone and cartilage degradation [4]. Pres-
ence of a joint effusion secondary to increased synovial
fluid production increases intra-articular pressure which
mechanically impedes blood/nutrient supply to the joint
and further exacerbates cellular damage [2]. There is
rapid progression and necrosis/degradation of chon-
drocytes within the first 24 h of onset [5, 6].
Corticosteroids are one well-established method of re-
ducing joint inflammation, having being used in rheuma-
toid arthritis for decades [7]. Pharmacodynamic effects
are mediated through binding to glucocorticoid receptors;
stimulating targeted protein upregulation (in particular
Lipocortin). There is subsequent inhibition of Phospholip-
ase A2 (a potent intracellular producer of prostaglandins,
free radicals and leukotrienes) as well as a deleterious ef-
fect on several pro-inflammatory cytokines such as IL-1,
Interferon (IFN)-γ and TNF-alpha. Other functions in-
clude inhibition of elastase and collagenase production,
decreased T-cell number and reduced synovial MMP-1
expression [8].
The use of glucocorticoids in infection has classically
been contra-indicated due to a theoretical risk of wors-
ening sepsis. Recent evidence regarding the use of corti-
costeroids alongside antibiotics in infection at other sites
has however brought this suggestion into question. Stud-
ies into severe sepsis [9], severe pneumonia [10], bacter-
ial meningitis [11] and acute pyelonephritis [12] have all
shown improved outcomes associated with steroid use.
Current research therefore suggests evidence for both
a positive effect of glucocorticoids on joint destruction
in arthritis, and improved clinical outcomes in infection
when combined with antibiotic therapy. It is hypothesised
that the combination of corticosteroids and antibiotics
could be of benefit when considering Septic Arthritis. This
study therefore sets out to examine the available evidence
on this research topic in the form of a systematic review
and meta-analysis.
Review
Methods
A computerised search of the databases MEDLINE and
CINAHL was conducted during November 2014 using
the EBSCOhost web search engine. This identified re-
search articles relating to the use of corticosteroids in
the treatment of septic arthritis. Search criteria included
combinations of the terms “steroids”, “hydrocortisone”,
“corticosteroids”, “dexamethasone”, “triamcinolone”, “pred-
nisolone”, “glucocorticoids”, “septic arthritis” and “joint in-
fection” via a Boolean/Phrase strategy applied to the full
text article and abstract. An outline of the full electronic
search strategy is shown in Table 1.
Search restrictions included English language text with
a publication date 1963–2014. Further potentially relevant
literature was identified through bibliographical analysis
of identified articles and using an internet search engine
(Google). Initial screening of potential articles was per-
formed through an independent abstract review. Relevant
articles were then discerned from those initially identified
with a thorough independent full text analysis. Inclusion
and exclusion criteria were used to ensure any conclusions
drawn from the literature were valid and based on a sound
methodical construct. Inclusion criteria comprised:
interventional articles relating to the concomitant use
of corticosteroids and antibiotics in the treatment of
septic arthritis; presence of a control group or cohort;
clearly stated inclusion and outcome criteria; assessment
of results using a validated appropriate statistical test and
ethical approval. Exclusion criteria included: No full text
availability and review articles.
Quality assessment was performed via the Cochrane
Collaboration’s risk of bias tool. No formal review protocol
was produced prior to the assessment process. All research
was conducted in accordance with current international
ethical standards [13].
Data extraction was carried out via a manual independ-
ent assessment of each article. Variables which were sought
included study design, study aim, sample size, subject
demographics, intervention, primary outcome measures,
results, and author’s conclusions. Meta-analysis of pooled
outcome measures was performed where possible (≥2
homogeneous randomised controlled studies with at
least one matched primary outcome variable) using the
Cochrane collaboration’s RevMan 5.3 tool [14].
The written report has been produced in concordance
with Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) guidelines [15].
Results
The search strategy revealed 223 unique articles which
were subjected to inclusion/exclusion criteria. Further ab-
stract analysis identified 11 of these as potential candidates
for review. A total of 6 articles were selected for study
inclusion. A flowchart diagram of the complete study
selection process is shown in Fig. 1. Articles consisted
Table 1 Search Criteria
Search 1: Steroids OR Corticosteroids OR Hydrocortisone OR
Dexamethasone OR Triamcinolone OR Prednisolone OR
Glucocorticoids (Search mode – Boolean/Phrase: 333,378 results).
Search 2: Septic Arthritis OR Joint Infection (Search mode – Boolean/Phrase,
7661 results)
Search 3: Search 1 AND Search 2 (Search mode – Boolean/Phrase:
223 results)
Farrow BMC Musculoskeletal Disorders  (2015) 16:241 Page 2 of 8
of 3 human studies in children (2 double-blind rando-
mised controlled trials & 1 double-blind non-randomised
controlled trial), and 3 animal studies (3 non-blinded
non-randomised controlled trials). No interventional hu-
man adult studies were available for analysis. All studies
showed a positive effect in at least one primary outcome
for the addition of corticosteroids to antibiotics in the
treatment of septic arthritis. A total of 349 participants
were involved in the analysis (209 humans, 57 rabbits and
83 mice). The mean age of human participants was
5.64 years. Individual study characteristics and results are
detailed in Table 2.
Fig. 1 Flowchart diagram of the complete study selection process
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Table 2 Individual study characteristics and results
Authors Design Aims Subjects Intervention Outcomes Results
Stricker
et al. 1996
[21]
Non-blinded
non-randomised
controlled trial
The chondroprotective effect of
betamethasone was examined
to determine if corticosteroids
can decrease articular cartilage
injury caused by inflammatory
exudate in Staphylococcus
aureus gonarthritis in rabbits
27 adolescent male
New Zealand white rabbits
split into 3 groups.
Each rabbit’s left knee was
inoculated with Staphylococcus
aureus. Group 1 received
antibiotics alone (intramuscular
Ceftriaxone for 12 days), group
2 received intramuscular
corticosteroids (4 days
Betamethasone) and antibiotics,
group 3 received intra-articular
glucocorticoids (single dose of
Betamethasone) and antibiotics.
All treatment was commenced
at 36 h after joint inoculation.
Synovial fluid culture & cell
count as well as peripheral
leukocyte count at days 2,
6 and 14. Histological and
histochemical analysis was
undertaken at 14 days.
A significant difference was
seen in mean peripheral
leukocyte count when
comparing group 1 and 2
at 14 days (5,100 vs 8,100
white blood cells, p < 0.05).
Group 2 showed statistically
greater safranin O stain
orthochromasia than Group
1 or 3 (p < 0.05) which was
thought to suggest
prostaglandin preservation.
This was consistent with
biochemical results for
hexosamine preservation
when group 2 was
compared to group 1
(p < 0.05)
Sakiniene
et al. 1996
[23]
Non-blinded
non-randomised
controlled trial
To evaluate the combined
effect of systemic
corticosteroids and antibiotics
on the course of septic arthritis
Two separate experimental
protocols were used: 1–40
five week old Swiss mice
(20 male, 20 female) split
into 3 groups. 2 – 43 male
Swiss nice (5–6 weeks old)
split into 3 groups. Results
of these experiments were
pooled.
In both studies mice were
initially inoculated with
Staphylococcus aureus. One
group received no treatment,
one group received antibiotics
alone (Cloxacillin given
intraperitoneally every 12 h)
and one group received
corticosteroids (Dexamethasone
given intraperitoneally every
24 h) and antibiotics.
Intervention was commenced
at 3 days post inoculation.
Frequency and severity of
arthritis (Arthritis index) at
0,3,7,14 days. Histopathological,
immunohistochemical,
bacteriologic, serologic and
haematologic manifestations
were assessed at 14 days.
Only those treated with
antibiotics and
corticosteroids showed a
significantly difference in
the frequency and severity
of arthritis compared to
controls at 14 days. Serum
levels of IFN-γ were 4 fold
decreased in the antibiotic
treated group and 15 fold
decreased in the
corticosteroid and antibiotic
group. Serum NO3− levels
were significantly reduced
in both the treatment arms.
Wysenbeek
et al. 1998
[24]
Non-blinded
non-randomised
controlled trial
To assess the effect of intra-
articular corticosteroids added
to systemic antibiotics in ex
perimental septic arthritis.
30 eight week old
New Zealand rabbits split
into 3 groups (n = 10 per
group).
Rabbits had their left knee
inoculated with Staphylococcus
epidermis. Group 1 were
untreated controls, group 2
were treated with antibiotics
alone (daily intramuscular
Cefonicid) and group 3
received glucocorticoids
(intra-articular Methylprednisolone
given 48 h after infection and 24 h
after antibiotic commencement)
and antibiotics
A composite score of
Histopathological-
histochemical parameters in
both a vertical (A) and
horizontal (B) section at
follow up (15 days).
Both treatment groups had
significantly lower scores
than the control. Group 3
had significantly lower
scores than group 2 for A
(6.5 [1.4] vs 4.0 [1.0], p =
0.001) and B (7.4 [2.6] vs
4.2 [2.2], p = 0.01) [] =
Standard Deviation (SD).
Odio et al.
2003 [17]
Double-blind
randomised
controlled trial
Assess the impact of
corticosteroids and antibiotics
on joint dysfunction and the
123 children with
documented septic arthritis
aged 3 months to 11 years
(with parental consent). 23
Placebo group received antibiotics
and IV 0.9 % saline (equivalent of
Dexamethasone timing and
volume). There was a variety of
Clinical outcomes were
assessed at the end of
treatment, 6 months and
12 months. During the
Levels of residual
dysfunction were
significantly improved for
Dexamethasone vs. Placebo
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Table 2 Individual study characteristics and results (Continued)
acute response in septic
arthritis.
children were unevaluable
therefore 100 patients were
assessed. There were two
groups: Dexamethasone
(n = 50) and Placebo (n = 50).
There were no significant
differences in baselines
characteristics between groups
antibiotic regimes used based on
age, identified pathogen and
organism resistance. Dexamethasone
group received antibiotics and IV
Dexamethasone (0.2 mg/kg/dose
given every 12 h for 8 doses).
Dexamethasone/Placebo given
from diagnosis.
acute phase time for
normalisation of CRP,
duration of symptoms,
extent of antibiotic therapy
and arthrotomy requirements
were also assessed.
at end of treatment (2 vs
16 [5.54–16.62], p < 0.001),
at 6 months (1 vs 19 [1.41–
4.22], p < 0.001) and 12
months (1 vs 13 [1.31–4.1],
p < 0.001) [] = 95 % CI.
Compared to placebo the
Dexamethasone group also
had quicker normalisation
of CRP (2.04 ± 1.25 vs 4.68 ±
6.23 days, p = 0.01); earlier
resolution of symptoms
(2.34 ± 5.06 vs 7.81 ± 2.04
days, p = 0.001); and shorter
duration of IV antibiotics
(7.2 ± 1.2 vs 10 ± 5.6,
p < 0.05). ± = SD
Harel et al.
2011 [16]
Double-blind
randomised
controlled trial
Evaluate the effect of adding
dexamethasone to antibiotic
therapy in the clinical course
of septic arthritis in children.
49 children aged 6–161 months
with confirmed septic arthritis.
There were two groups:
Dexamethasone (n = 24) and
Placebo (n = 25)
Placebo group received antibiotics
(IV Cefuroxime 150 mg/kg/day in 3
divided doses) and placebo (IV 0.9 %
saline at equivalent of
Dexamethasone timing and
volume). Dexamethasone group
received antibiotics and IV
Dexamethasone (0.15 mg/kg/dose)
every 6 h for 16 consecutive doses.
Dexamethasone/Placebo given from
diagnosis.
Comparison between groups
for clinical and laboratory
parameters, length of hospital
stay, and late sequelae (follow
up at 2,6,12 months).
Compared to placebo those
treated with Dexamethasone
had a shorter duration of
fever (1.68 [2.57] vs 2.38
[2.41] for first day without
fever, p = 0.021); quicker
normalisation of CRP (3.09
[3.80] vs 5.48 [4.69] days,
p = 0.029); and duration of
IV antibiotics (9.91 [4.84] vs
12.60 [5.20] days, p = 0.007).
No formal assessment of
late sequelae or length of
hospital stay was
performed. [] = SD
Arti et al.
2014 [18]
Double-blind
non-randomized
controlled trial
Evaluation of the effects of
IV dexamethasone on the
recovery process in septic
arthritis
60 patients with septic arthritis
separated into two groups
(n = 30). Mean age in group 1
was 8.06 ± 0.5 years. 73 % of
the group 1 participants were
male and 27 % were female.
Mean age in group 2 was
8 ± 0.6 years. 70 % of the
group 1 participants were
male and 30 % were female.
Group 1 received IV antibiotics
(dose & timing not detailed) and IV
Dexamethasone (0.15 mg/kg/dose
every 6 h for 4 days). Group 2
received antibiotics and placebo
(IV 0.9 % saline given at same
volume and timing as
Dexamethasone). Dexamethasone/
Placebo given from diagnosis.
Groups were compared
regarding clinical
(inflammation & redness,
range of motion (ROM), and
duration of therapy) and
laboratory findings
(ESR & CRP).
There was a significant
difference between groups
1 & 2 regarding redness &
inflammation (2.43 ± 0.15 vs
6.53 ± 0.27 days, p = 0.0014);
days of hospitalisation
(8.9 ± 0.88 vs 12.17 ± 0.54
days, p = 0.005); joint ROM
(91.2 ± 2.28 vs 40.53 ± 1.44°,
p = 0.008); and reduction of
ESR levels (36.03 ± 2.77 vs
16.73 ± 0.83, p = 0.0001)
± = SD
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Quantitative synthesis (meta-analysis) was only pos-
sible regarding two primary outcomes for two of the in-
cluded studies – time to normalisation of CRP (Fig. 2)
and duration of intra-venous (IV) antibiotic therapy
(Fig. 3). A risk of bias table detailing the author’s judge-
ments about each risk of bias item for each included
study is shown in Fig. 4.
Discussion
There was a significant lack of adult human interven-
tional trial data available. All studies did however show a
positive effect in at least one primary outcome for the
addition of corticosteroids to antibiotics in the treatment
of septic arthritis. These improvements were shown
across a variety of cellular, histological and clinical levels.
Meta-analysis regarding normalisation of CRP and dur-
ation of IV antibiotics was performed with statistically
significant trends favouring the addition of Dexametha-
sone vs. placebo for both. A lack of available studies and
participant numbers to provide substantial analysis were
however noted. No study documented adverse events as-
sociated with glucocorticoid use. These results are in
keeping with those examining the addition of corticoste-
roids to antibiotics at other anatomical sites. Whilst
these results are promising, there is a lack of large ran-
domised controlled trial evidence with long term follow
up and safety data in adult human subject’s. As such
there is currently insufficient evidence to recommend
corticosteroids alongside antibiotics for the treatment of
septic arthritis.
The studies identified during the review process were
of varying methodological quality. There were two double-
blind randomised controlled trials identified during the
search process [16, 17]. Both of these used a placebo con-
trolled design to provide evidence for a positive effect in
both biological and clinical parameters for dexamethasone
in addition to antibiotic therapy. The numbers involved
were however small, and there were some flaws identified
in the methodological design of both studies. For example
both articles failed to document if there was blinding of
outcome assessment; determine whether appraisal was per-
formed on an intention-to-treat or per-protocol; perform
any formal safety analysis; and account for the impact of
surgical intervention on outcomes. In addition despite
documentation of duration of hospitalisation as a primary
outcome in Harel et al. 2011 [16] the results and statistical
analysis were not included in the published article. This
study also failed to perform any statistical assessment of
long term outcomes – possibly due to significant partici-
pant attrition at 12 months follow up.
The other human study by Arti et al. 2014 [18] also
found a positive effect for Dexamethasone therapy along-
side antibiotics with regards to number of days of hospi-
talisation, clinical outcomes, and laboratory findings. This
study had a number of major methodological flaws such
as lack of randomisation, failure to compare baseline char-
acteristics between groups and no long term follow up. It
was therefore felt to provide minimal additional informa-
tion to the previous literature.
The remaining studies focused upon the use of corti-
costeroids alongside antibiotics in an animal model. These
allowed for direct analysis of histopathological parameters
not easily assessed in humans due to ethical concerns. All
studies showed an improvement in arthritis severity with
the addition of glucocorticoids to antibiotics. Despite the
poor methodological quality of the research and the lack
of direct applicability to humans these articles do provide
valid scientific rationale for the use of corticosteroids in
septic arthritis.
There are still however a number of unanswered ques-
tions regarding the use of corticosteroids in Septic Arth-
ritis. Importantly the concerns coming from a previously
identified association between the use of glucocorticoids
and an increased risk of infection [19] have not yet been
fully addressed. Although no study assessed during this
analysis identified any safety issues during follow up this
was not formally evaluated at any point. A recently pub-
lished abstract did report safety during a retrospective
analysis regarding the use of corticosteroids in septic
arthritis with no side effects noted except for 3 cases of
symptom rebound after completion of the steroid course.
This is a previously established side effect of steroid with-
drawal [20]. It is also important to consider the significant
long term effects of steroid use such as osteoporosis, dia-
betes, raised blood pressure, weight gain, mood changes
and gastric irritation. It is felt however that the duration
and dose of corticosteroids used in this scenario (such as
the 4 days of IV Dexamethasone used in Odio et al. 2003
Fig. 2 Forest plot – meta-analysis of days to normalisation of CRP for Odio et al. 2003 & Harel et al. 2011
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[17] and Harel et al. 2011 [16]) would be unlikely to have
any significant long term effect. The optimum route, dur-
ation and dose of glucocorticoids need to be determined
as well. Comparisons between intramuscular and intra-
articular corticosteroids in the Stricker et al. 1996 [21]
study did appear to favour an increased effect with the
parenteral route. No study has examined the oral route of
administration.
This study has also highlighted issues regarding the
generalisability of current evidence. So far all studies
have focused upon a child population and therefore the
impact on and adult cohort is still unknown. It can be
hypothesised that known differences in immunology
between varying age groups [22] could impact on the
glucocorticoid response.
Conclusions
The current evidence base points strongly towards a bene-
ficial effect for corticosteroids in septic arthritis. This is
consistent with scientific rationale and data regarding
glucocorticoid use in sepsis at other anatomical sites.
There is however insufficient evidence to make treatment
recommendations at present. Further large scale rando-
mised controlled trials including adult subjects; safety pro-
files and long term efficacy are required for this promising
therapeutic option.
Competing interests
The author declares that he has no competing interests.
Authors’ contributions
L. Farrow is the sole author of this paper and is therefore responsible for the
entirety of the collected work.
Received: 28 April 2015 Accepted: 28 August 2015
References
1. Weston VC, Jones AC, Bradbury N, Fawthrop F, Doherty M. Clinical features
and outcome of septic arthritis in a single UK Health District 1982–1991.
Ann Rheum Dis. 1999;58:214–9.
2. Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev. 2002;15:527–44.
3. Colavite PM, Sartori A. Septic arthritis: immunopathogenesis, experimental
models and therapy. J Venom Anim Toxins incl Trop Dis. 2014;20:19.
4. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL,
TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine
Growth Factor Rev. 2004;15:49–60.
5. Smith RL, Merchant TC, Schurman DJ. In vitro cartilage degradation by
Escherichia coli and Staphylococcus aureus. Arthritis Rheum. 1982;25:441–6.
6. Roy S, Bhawan J. Ultrastructure of articular cartilage in pyogenic arthritis.
Arch Pathol. 1975;99:44–7.
7. Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H. Exogenous and
endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 2011;63:1–9.
8. Townsend HB, Saag KG. Glucocorticoid use in rheumatoid arthritis: benefits,
mechanisms, and risks. Clin Exp Rheumatol. 2004;22:S77–82.
9. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R,
et al. Corticosteroids in the treatment of severe sepsis and septic shock in
adults: a systematic review. JAMA. 2009;301:2362–75.
10. Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid
treatment for severe pneumonia caused by 2009 H1N1 influenza virus.
Crit Care. 2011;15:413.
11. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute
bacterial meningitis. Cochrane Database Syst Rev. 2013;6, CD004405.
12. Pohl HG, Rushton HG, Park JS, Chandra R, Majd M. Adjunctive oral
corticosteroids reduce renal scarring: the piglet model of reflux and acute
experimental pyelonephritis. J Urol. 1999;162:815–20.
Fig. 4 A risk of bias table detailing the author’s judgements about
each risk of bias item for each included study
Fig. 3 Forest plot – meta-analysis of duration of IV antibiotics for Odio et al. 2003 & Harel et al. 2011
Farrow BMC Musculoskeletal Disorders  (2015) 16:241 Page 7 of 8
13. Padulo J, Oliva F, Frizziero A, Maffulli N. Muscle, Ligaments and Tendons
Journal. Basic principles and recommendations in clinical and field science
research. Muscles Ligaments Tendons J. 2013;3:250–2.
14. Review Manager (RevMan) [Computer Program] Version 5.3 Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
http://tech.cochrane.org/revman/about-revman-5
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
BMJ. 2009;339:b2535.
16. Harel L, Prais D, Bar-On E, Livni G, Hoffer V, Uziel Y, et al. Dexamethasone
therapy for septic arthritis in children: results of a randomized double-blind
placebo-controlled study. J Pediatr Orthop. 2011;31:211–5.
17. Odio CM, Ramirez T, Arias G, Abdelnour A, Hidalgo I, Herrera ML, et al.
Double blind, randomized, placebo-controlled study of dexamethasone
therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J.
2003;22:883–8.
18. Arti H, Mousapour A, Alavi SM. The effect of intravenous dexamethasone in
the treatment of septic arthritis. Pak J Med Sci. 2014;30:955–7.
19. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S,
et al. Immediate and delayed impact of oral glucocorticoid therapy on risk
of serious infection in older patients with rheumatoid arthritis: a nested
case–control analysis. Ann Rheum Dis. 2012;71:1128–33.
20. Margolin L, Cope DK, Bakst-Sisser R, Greenspan J. The steroid withdrawal
syndrome: a review of the implications, etiology, and treatments. J Pain
Symptom Manage. 2007;33:224–8.
21. Stricker SJ, Lozman PR, Makowski AL, Gunja-Smith Z. Chondroprotective
effect of betamethasone in lapine pyogenic arthritis. J Pediatr Orthop.
1996;16:231–6.
22. DelaRosa O, Pawelec G, Peralbo E, Wikby A, Mariani E, Mocchegiani E, et al.
Immunological biomarkers of ageing in man: changes in both innate and
adaptive immunity are associated with health and longevity. Biogerontology.
2006;7:471–81.
23. Sakiniene E, Bremell T, Tarkowski A. Addition of corticosteroids to antibiotic
treatment ameliorates the course of experimental Staphylococcus aureus
arthritis. Arthritis Rheum. 1996;39:1596–605.
24. Wysenbeek AJ, Volchek J, Amit M, Robinson D, Boldur I, Nevo Z. Treatment
of staphylococcal septic arthritis in rabbits by systemic antibiotics and
intra-articular corticosteroids. Ann Rheum Dis. 1998;57:687–90.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Farrow BMC Musculoskeletal Disorders  (2015) 16:241 Page 8 of 8
